Mu-Chun Li
Overview
Explore the profile of Mu-Chun Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
209
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tahiliani H, Dhayalan A, Li M, Hsieh H, Coumar M
Bioorg Chem
. 2024 Dec;
154:108019.
PMID: 39689509
Aldehydes are organic compounds containing a carbonyl group found exogenously or produced by normal metabolic processes and their accumulation can lead to toxicity if not cleared. Aldehyde dehydrogenases (ALDHs) are...
2.
Shih W, Huang H, HuangFu W, Lin T, Sung T, Li M, et al.
Int J Biol Macromol
. 2024 Nov;
283(Pt 1):137296.
PMID: 39515714
Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options, underscoring the urgent need for developing new therapies. The upregulation of TBK1 activity plays a crucial role in multiple pancreatic cancer-related signaling...
3.
Li M, Lai Y, Kuo P, Reddy J, Chen C, Manimala J, et al.
J Med Chem
. 2024 Jun;
67(13):10906-10927.
PMID: 38913493
A series of bifunctional compounds have been discovered for their dual functionality as MER/AXL inhibitors and immune modulators. The furanopyrimidine scaffold, renowned for its suitability in kinase inhibitor discovery, offers...
4.
Li M, Coumar M, Lin S, Lin Y, Huang G, Chen C, et al.
J Med Chem
. 2023 Feb;
66(4):2566-2588.
PMID: 36749735
The development of orally bioavailable, furanopyrimidine-based double-mutant (L858R/T790M) EGFR inhibitors is described. First, selectivity for mutant EGFR was accomplished by replacing the ()-2-phenylglycinol moiety of with either an ethanol or...
5.
Kumari M, Lu R, Li M, Huang J, Hsu F, Ko S, et al.
J Biomed Sci
. 2022 Sep;
29(1):68.
PMID: 36096815
The novel coronavirus disease (COVID-19) pandemic remains a global public health crisis, presenting a broad range of challenges. To help address some of the main problems, the scientific community has...
6.
Li M, Lin W, Wang P, Su Y, Chen P, Fan C, et al.
Eur J Med Chem
. 2021 Jul;
224:113673.
PMID: 34303872
Rare oncogenic NTRK gene fusions result in uncontrolled TRK signaling leading to various adult and pediatric solid tumors. Based on the architecture of our multi-targeted clinical candidate BPR1K871 (10), we...
7.
Chandar Charles M, Li M, Hsieh H, Coumar M
ACS Omega
. 2021 Mar;
6(9):6100-6111.
PMID: 33718701
G9a protein methyltransferase is a potential epigenetic drug target in different cancers and other disease conditions overexpressing the enzyme. G9a is responsible for the H3K9 dimethylation mark, which epigenetically regulates...
8.
Blay V, Li M, Ho S, Stoller M, Hsieh H, Houston D
Acta Pharm Sin B
. 2020 Sep;
10(7):1309-1320.
PMID: 32874830
Hepsin, a transmembrane serine protease abundant in renal endothelial cells, is a promising therapeutic target against several cancers, particularly prostate cancer. It is involved in the release and polymerization of...
9.
Lin S, Chang C, Coumar M, Chen P, Kuo F, Chen C, et al.
Bioorg Chem
. 2020 Mar;
98:103689.
PMID: 32171993
In an effort to develop new cancer therapeutics, we have reported clinical candidate BPR1K871 (1) as a potentanticancercompound in MOLM-13 and MV4-11 leukemia models, as well as in colorectal and...
10.
Tsai H, Su C, Kok V, Li M
Eur J Obstet Gynecol Reprod Biol
. 2012 Apr;
162(2):235-6.
PMID: 22465828
No abstract available.